Abiopharma

🔍 Berger Dietmar (Executive)

Company: GILEAD SCIENCES, INC. (GILD)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 16,326 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 16,326.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,944 shares of Common Stock at $121.6 per share (Direct)
  Date: 2026-01-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 9,382.00 | transaction_form_type: 4
• Sold 16,326 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 41,179.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2

Footnotes:

• F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
• F2: The restricted stock units vest in approximately three equal installments on the first three anniversaries of the date of grant until fully vested.